New research on lung cancer causing gene hailed as important step towards new cancer therapies.

Researchers at Okayama University have revealed an approach for suppressing the expression of the SOX2 protein, a cancer causing gene associated with both lung and esophageal cancer.

The procedure, based on the targeted delivery of a specially designed artificial protein, may signify an important step towards new cancer therapies.

Most cancer-related deaths world-wide are caused by lung cancer.

For one type of lung cancer, lung squamous cell carcinoma (SCC), a protein called SOX2 is known to be a candidate oncogene — a gene that, under certain conditions, can transform a cell into a tumorous cell.

A team of researchers led by Professor Takashi Sera from Okayama University has now found a method for suppressing SOX2 expression in cancer cells.

The scientists’ approach involves a so-called artificial transcription factor (ATF) — a protein that regulates the production of a gene — and may lead to an effective therapy for not only lung SCC but also esophageal SCC.

The ATF created by Professor Sera and colleagues acting as a SOX2 suppressor is based on ‘zinc finger’ structures: protein motifs featuring stabilizing zinc ions.

The researchers first showed that introduction of their ATF compound (labeled ATF/SOX2), consisting of 6 zinc-finger arrays, indeed leads to the suppression of SOX2 expression in vitro.

They also confirmed that the ATF did not affect the viability of normal human cells. In a mouse model, ATF/SOX2 inhibited lung SCC tumor growth, confirming the effect of suppression of SOX2 in vivo.

Regarding the prospect of developing an SSC therapy based on ATF/SOX2, the scientists point out that an advantage of using ATFs is their small molecular weight, making it relatively easy to deliver them to target cells.

They also note that ATFs can fuse with cell-penetrating peptides, providing a potential mechanism for the actual delivery.

Moreover, this protein delivery approach is independent of cell type and there’s no risk of mutagenesis (a change in the genetic information of an organism).

Professor Sera and colleagues conclude that, although certain challenges still have to be overcome, “We have used ATF technology to successfully suppress SCC in vitro and in vivo … as a first step in the search for an effective treatment for SCC lung and esophageal cancers.”

Further information can be found on the Okayama University Website here

- Press Association


Related Articles

'Vulnerable patients are being targeted' - Averil Power welcomes ban on cancer treatment ads

Equal access to HPV vaccine from September

Radiology staff and resources ‘in short supply’

Solicitor calls on HSE not to force Kerry patients to 'run the full gamut' of High Court proceedings

More in this Section

Brexiteers launch alternative vision for Withdrawal Agreement

Banker 'texted partner after high-class escort was bludgeoned to death,' murder trial hears

Trump’s ex-lawyer Michael Cohen gets three years in prison

LIVE: Theresa Mary will not lead Tories into next election


Lifestyle

Unmasking Limerick's newest masked rapper

How to stop tensions boiling over this festive season

Decorating your house for Christmas? Here's some advice from three Irish interior designers

A look back at the 10 big stories form the year in music

More From The Irish Examiner